pdf   xlsx method abbreviations

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2), ... , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 1.01 [0.89, 1.15]< 113%3 studies (3/-)45.2 %lownot evaluable highcrucial-
progression or deaths (PFS) 0.75 [0.58, 0.98]< 179%3 studies (3/-)98.1 %lownot evaluable highimportant-
objective responses (ORR) 2.78 [1.11, 6.97]> 169%3 studies (3/-)98.5 %lownot evaluable highnon important-

safety endpoints 00

AE leading to treatment discontinuation (any grade) 11.74 [2.82, 48.89]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
SAE (any grade) 1.13 [0.82, 1.56]< 10%1 study (1/-)23.3 %NAnot evaluable non important-
TRAE (any grade) 1.77 [1.07, 2.93]< 10%1 study (1/-)1.3 %NAnot evaluable non important-
TRAE (grade 3-4) 1.68 [1.23, 2.28]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
TRAE leading to death (grade 5) 2.06 [0.55, 7.72]< 10%3 studies (3/-)14.2 %lownot evaluable highnon important-
TRAE leading to discontinuation (any grade) 3.74 [0.76, 18.52]< 10%1 study (1/-)5.3 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.